Eisai Pharmaceuticals India
↗Mumbai, India
Eisai Pharmaceuticals India is a wholly-owned subsidiary of the Japanese global pharmaceutical giant Eisai Co., Ltd. The Indian entity is a critical hub for the parent company's global operations, housing the 'Eisai Knowledge Centre' (EKC) in Visakhapatnam, which integrates API (Active Pharmaceutical Ingredient) research, process development, and large-scale manufacturing.
Eisai India focuses on therapeutic areas including Oncology, Neurology (specifically Alzheimer's and Epilepsy), and Gastroenterology. The company is currently undergoing a significant digital transformation, marked by the launch of a new Global Capability Centre (GCC) in 2026 to support global data science and healthcare technology initiatives.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Neurology and Oncology Therapeutics
SIZE & FINANCIALS
Employees:501-1000
Revenue:$45M - $55M (India specific; FY2025 revenue ~402 Cr INR)
Founded:2004
Ownership:subsidiary
Status:operating
FUNDING
Investors:Eisai Co., Ltd. (100% ownership)
STOCK
Exchange:TYO (Parent: 4523)
Ticker:4523
Market Cap:$18.5B (Parent Company)
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Leqembi, Lenvima)
Modalities:Small molecule, mAb (Monoclonal Antibody)
Active Trials:85
Trial Phases:Phase 1: 25 | Phase 2: 30 | Phase 3: 20 | Phase 4: 10
FDA Approvals:12
EMA Approvals:10
CORPORATE STRUCTURE
Parent Company:Eisai Co., Ltd. (Japan)
Subsidiaries:Eisai Pharmatechnology and Manufacturing Pvt. Ltd.
Key Partnerships:Biogen (Co-development of Leqembi), Merck & Co. (Lenvima/Keytruda collaboration), BioArctic (Lecanemab research), Fosun Pharma (Serplulimab licensing)
COMPETITION
Position:Leader in Alzheimer's disease (first-to-market with disease-modifying therapy Leqembi) and a strong niche player in Oncology.
Competitors:Eli Lilly, Biogen, Roche, Pfizer, Sun Pharma (India)
LEADERSHIP
Key Executives:
Hideshi Yamamoto - Managing Director, Eisai India
Girish Dixit - Executive Director
Scientific Founders:Toyoji Naito
Board Members:Takuya Kijima, Shohei Kanazawa, Kazuhiko Tamura
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Eisai Pharmaceuticals India. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.